Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients: An 18-week, randomized, double-blind study

Diabetes Care

Volumn 29, Issue 3, 2006, Pages 515-520

  Moulin, Philippe ^a,i   Andre, Marie ^b   Alawi, Hasan ^c   Dos Santos, Lelita C ^d   Khalid, Abdul K ^e   Koev, Dragomir ^f   Moore, Ray ^g   Serban, Viorel ^h   Picandet, Brigitte ^b   Francillard, Marie ^b  

^a UNIVERSITÉ LYON 1   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c Schwerpunkt Diabetologie Klinik   (Germany)

^d CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^e Hospital Kebangsaan Malaysia   (Malaysia)

^f UNIVERSITY OF SOFIA   (Bulgaria)

^g Umhlanga Hospital   (South Africa)

^h Spitalul Judetean   (Romania)

ⁱ LOUIS PRADEL HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENFLUOREX; HEMOGLOBIN A1C; METFORMIN; PLACEBO; SULFONYLUREA; DRUG DERIVATIVE; FENFLURAMINE; GLYCOSYLATED HEMOGLOBIN; SULFONYLUREA DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANALYSIS OF COVARIANCE; ARTICLE; BILIARY TRACT DISEASE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HEADACHE; HEART FAILURE; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY CYST; PLEURA METASTASIS; PYELONEPHRITIS; RADICULOPATHY; RANDOMIZED CONTROLLED TRIAL; DRUG COMBINATION; METABOLISM; MIDDLE AGED;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FENFLURAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS;

EID: 33744996455     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/diacare.29.03.06.dc05-1439     Document Type: Article

References (17)

1. European Diabetes Policy Group 1999: A desktop guide to type 2 diabetes mellitus. Diabet Med 16:716-730, 1999
2. American Diabetes Association: Standards of medical care in diabetes. Diabetes Care (Suppl. 1)28:S4-S36, 2005
3. Howlett HC, Bailey CJ: A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 20:489-503, 1999
4. Kohl C, Ravel D, Girard J, Pegorier JP: Effects of benfluorex on fatty acid and glucose metabolism in isolated rat hepatocytes: from metabolic fluxes to gene expression. Diabetes 51:2363-2368, 2002
5. Bianchi R, Bongers V, Bravenboer B, Erkelens DW: Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. Diabetes Care 16:557-559, 1993
6. De Feo P, Lavielle R, De Gregoris P, Bolli GB: Anti-hyperglycaemic mechanisms of benfluorex in type II diabetes mellitus. Diabetes Metab Rev 9 (Suppl. 1):35S-41S, 1993
7. Riccio A, Vigili de Kreutzenberg S, Dorella M, Da Tos V, De Biasi L, Marescotti MC, Tiengo A, Del Prato S: Mechanism(s) of the blood glucose lowering action of benfluorex. Diabetes Metab Rev 9 (Suppl. 1): 19S-27S, 1993
8. Stucci N, De Gregoris P, Lavielle R, Tomasi F: Therapeutic benefit of benfluorex in type II diabetic patients treated with sulfonylureas. J Diabetes Complications 10:267-273, 1996
9. Del Prato S, Erkelens DW, Leutenegger M: Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients. Acta Diabetol 44:20-27, 2003
10. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
12. The European Agency for the Evaluation of Medicinal Products: Evaluation of Medicines for Human Use. London, May 2002 (CPMP/EWP/1080/00)
13. NCEP Adult Treatment Panel III: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
14. Grundy SM, Cleeman JI, Merz NB, Brewer B Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, for the Coordinating Committee of the National Cholesterol Education Program: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239, 2004
15. U.K. Prospective Diabetes Study Group: Association of glycaemia with macrovascular and microvascular complications of type II diabetes: prospective observational study (UKPDS 35). BMJ 321:405-412, 2000
16. Rosiglitazone Prescribing Information 2004. GlaxoSmithKline Clinical Trial Register - Clinical Trial Information for Study 49653/015
17. Rosiglitazone prescribing information 2004. GlaxoSmithKline Clinical Trial Register - Clinical Trial Information for Study 49653/096